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Should you still recommend 
omega-3 supplements?
Probably not. A new meta-analysis adds to a growing 
body of evidence that omega-3 fatty acids do little  
to protect against heart disease.
PRACTICE CHANGER
Stop recommending omega-3 fatty acid sup-
plements for cardiovascular protection. They 
have no significant impact on all-cause mor-
tality, acute myocardial infarction, sudden 
death, or stroke.1
strength of recommendation
A: Based on a meta-analysis of randomized 
controlled trials (RCTs).
Rizos E, Ntzani E, Bika E, et al. Association between omega-3 fatty acid 
supplementation and risk of major cardiovascular disease events: a 
systematic review and meta-analysis. JAMA. 2012;308:1024-1033.
ILLUSTRATIVE CASE
a 59–year-old patient who had a myocardial 
infarction (mi) 3 years ago is taking an ace 
inhibitor, a statin, and a b-blocker. he asks you 
whether he should also take omega-3 fatty 
acid supplements to further decrease his risk 
of heart disease. What should you tell him? 
Coronary artery disease (CAD) kills more than 500,000 Americans ev-ery year,2 and medical and dietary 
therapies for primary and secondary car-
diovascular protection are paramount. 
Omega-3 polyunsaturated fatty acid (PUFA) 
supplementation is one such therapy. 
Omega-3 PUFAs are precursors to certain 
prostaglandins that decrease the proinflam-
matory state in patients with CAD. They also 
lower triglyceride levels and produce an 
anti arrhythmic effect by promoting electrical 
stability. 
But do PUFA supplements  
provide cardioprotection?
The American Heart Association’s Nutrition 
Committee recommends either omega-3 
PUFA supplementation with 250 to 500 mg 
eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA) per day or 2 servings 
of oily fish per week for both primary and 
secondary prevention of CAD.3 The European 
Society of Cardiology also encourages in-
creased consumption of oily fish.4 
These recommendations are based on 
primary and secondary prevention stud-
ies, performed between 1989 and 2007, that 
found a 15% to 29% decrease in all-cause 
mortality and nonfatal cardiovascular events 
associated with regular intake of omega-3 
fatty acids.5-7 The systematic review and meta-
analysis detailed below revisited the effect of 
omega-3 supplementation on major cardio-
vascular outcomes.1
STUDY SUMMARY 
omega-3 supplements  
don’t lower cardiovascular risk
This meta-analysis included 20 RCTs with a 
total of 68,680 patients. The median age was 
68 years, with a range from 49 to 70 years. 
Thirteen of the studies evaluated omega-3 
PUFAs for secondary prevention of cardio-
vascular outcomes, 4 assessed both primary 
and secondary prevention, and 3 looked at 
outcomes in patients with implantable car-
dioverter defibrillators. All lasted longer than 
conTinued
one year, and most were high quality, with a 
low risk of bias.
The median treatment duration was 
2 years, with a maximum of 6.2 years. The mean 
omega-3 PUFA dose evaluated in the studies 
was 1.5 g per day, with the exception of 2 stud-
ies in which patients received omega-3 PUFAs 
through dietary sources. Twelve studies used a 
dose of 1 g or more per day. Half of the included 
trials were performed during the period when 
statins were routinely prescribed for cardiovas-
cular risk modification (1998 or later). 
Outcomes included all-cause mortality 
(17 studies), cardiac death (13 studies), sud-
den death (7 studies), MI (13 studies), and 
stroke (9 studies).
This meta-analysis found trends to-
ward a decrease in all-cause mortality, car-
diac death, sudden death, and MI in patients 
taking omega-3 PUFAs, but no statistically 
significant association between any of the 
outcomes and omega-3 PUFA supplementa-
tion. The relative risk for all-cause mortality 
was 0.96 (95% confidence interval, 0.91-1.02; 
P=.17). Prespecified subgroup analysis found 
no association between treatment effect and 
omega-3 fatty acid dose.
Are dietary sources of omega-3s  
more effective? 
In the 2 trials involving dietary supplemen-
tation with omega-3 PUFAs, the results for 
all-cause mortality and cardiac death were 
conflicting, with one showing an increase in 
all-cause mortality and cardiac death and the 
other showing a decrease in both outcomes 
compared with the control group. 
No harmful effects of omega-3 PUFAs 
were found in either the supplement- or diet-
based studies.
WHAT’S NEW 
More evidence of little benefit 
The meta-analysis by Rizos et al is the most 
up-to-date, comprehensive look at the value 
of omega-3 fatty acids for primary and sec-
ondary prevention of cardiovascular events. 
It differs from previous reviews in that most 
included studies were well-done RCTs. In 
addition, the studies were performed in 
both primary and secondary cardiovascu-
lar disease prevention settings and involved 
different forms of omega-3 PUFA supple-
mentation, including dietary sources and 
supplements. The trials were predominantly 
larger than those included in previous sys-
tematic reviews, as well. The baseline risk for 
cardiovascular disease in the newer studies 
(7 of the 20 RCTs were completed after 2007) 
may be different from that of previous studies 
because of increased use of certain medica-
tions, such as statins. 
In recent years, other studies of omega-3 
PUFAs have had similar results. A meta- 
analysis of 14 RCTs found that omega-3 PUFA 
supplementation offered no benefit for the 
secondary prevention of cardiovascular dis-
ease.8 The FORWARD trial—published earlier 
this year—showed that omega-3 PUFAs did 
not decrease the recurrence of atrial fibrilla-
tion in patients with a history of confirmed 
paroxysmal atrial fibrillation.9 And an earlier 
(2006) analysis of RCTs and cohort studies 
found no benefit from omega-3 fatty acids for 
primary prevention of cardiovascular disease 
or cancer.10 
CAVEATS
No significant help, and no harm 
While this meta-analysis found no statis-
tically significant benefits from omega-3 
PUFAs, there is no evidence of harm from 
PUFA intake, whether from dietary sources or 
supplements. There is no need to tell patients 
who wish to take omega-3 supplements not 
to do so. But we should not promote their use 
for the sole purpose of cardiovascular disease 
prevention. 
CHALLENGES TO IMPLEMENTATION
Changing minds won’t be easy 
Despite recent findings indicating that 
omega-3 PUFAs provide little primary or 
secondary protection against cardiovascular 
events, advertising from supplement manu-
facturers may make it hard to change pa-
tients’ minds. Because diets and supplements 
containing these fatty acids do not cause ap-
parent harm, patients and physicians may 
decide that a small potential benefit is worth 
the expense.                  JFP
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